Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 8;116(5):642-646.
doi: 10.1093/jnci/djae013.

Accelerating pediatric Hodgkin lymphoma research: the Hodgkin Lymphoma Data Collaboration (NODAL)

Kirk D Wyatt  1 , Suzi Birz  2 , Sharon M Castellino  3   4 , Tara O Henderson  2 , John T Lucas Jr  5 , Qinglin Pei  6 , Yiwang Zhou  7 , Samuel L Volchenboum  2 , Brian Furner  2 , Michael Watkins  2 , Kara M Kelly  8 , Jamie E Flerlage  9 ; Hodgkin Lymphoma Data Collaboration (NODAL)
Collaborators, Affiliations

Accelerating pediatric Hodgkin lymphoma research: the Hodgkin Lymphoma Data Collaboration (NODAL)

Kirk D Wyatt et al. J Natl Cancer Inst. .

Abstract

Data commons have proven to be an indispensable avenue for advancing pediatric cancer research by serving as unified information technology platforms that, when coupled with data standards, facilitate data sharing. The Pediatric Cancer Data Commons, the flagship project of Data for the Common Good (D4CG), collaborates with disease-based consortia to facilitate development of clinical data standards, harmonization and pooling of clinical data from disparate sources, establishment of governance structure, and sharing of clinical data. In the interest of international collaboration, researchers developed the Hodgkin Lymphoma Data Collaboration and forged a relationship with the Pediatric Cancer Data Commons to establish a data commons for pediatric Hodgkin lymphoma. Herein, we describe the progress made in the formation of Hodgkin Lymphoma Data Collaboration and foundational goals to advance pediatric Hodgkin lymphoma research.

PubMed Disclaimer

Conflict of interest statement

T.H., who is a JNCI associate editor and co-author on this paper, was not involved in the editorial review or decision to publish the manuscript. The authors have no relevant conflicts of interest to disclose relating to this work.

Figures

Figure 1.
Figure 1.
Hodgkin lymphoma related data elements currently available (bolded) and anticipated (non-bolded) in the PCDC.
Figure 2.
Figure 2.
Using NODAL to enhance collaborative research in pediatric and adolescent Hodgkin lymphoma. Figure created with BioRender.com and published under license.
See this image and copyright information in PMC

References

    1. Castellino SM, Pei Q, Parsons SK, et al.Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma. N Engl J Med. 2022;387(18):1649-1660. - PMC - PubMed
    1. Smith MA, Seibel NL, Altekruse SF, et al.Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625-2634. - PMC - PubMed
    1. Flerlage JE, Hiniker SM, Armenian S, et al.Pediatric Hodgkin lymphoma, version 3.2021. J Natl Compr Canc Netw. 2021;19(6):733-754. - PubMed
    1. Flerlage JE, Kelly KM, Beishuizen A, et al.Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): methodology statement. Pediatr Blood Cancer. 2017;64(7). doi:10.1002/pbc.26421 - DOI - PubMed
    1. Hall MD, Terezakis SA, Lucas JT, et al.Radiation therapy across pediatric Hodgkin lymphoma research group protocols: a report from the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group. Int J Radiat Oncol Biol Phys. 2022;112(2):317-334. - PMC - PubMed

Publication types